{"id":"W4313453663","doi":"10.1002/ajh.26809","title":"Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study","year":2023,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Microsemi (Canada); McGill University; Jewish General Hospital","funders":"","keywords":"Venetoclax; Medicine; Lymphoma; Brentuximab vedotin; Obinutuzumab; Follicular lymphoma; Rituximab; Oncology; Internal medicine; Antibody-drug conjugate; Cancer research; Antibody; Immunology; Chronic lymphocytic leukemia; Leukemia; Monoclonal antibody; CD30","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000526316,0.0004043375,0.0007125727,0.0002489848,0.0001733725,0.0006031828,0.0004435722,0.0003554969,0.001000886],"category_scores_gemma":[0.0002311449,0.0001619927,0.0003350616,0.0002314374,0.0003132808,0.0003704745,0.0001527584,0.001372911,0.0001709388],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005004794,"about_ca_system_score_gemma":0.0004935852,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001120494,"about_ca_topic_score_gemma":0.002888643,"domain_scores_codex":[0.9998186,0.00006177222,0.000008362846,0.00002087628,0.00003141062,0.00005890041],"domain_scores_gemma":[0.9998684,0.00002349045,0.00003005171,0.00001795015,0.00001127566,0.00004884852],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.0274538,0.02184832,0.002669235,0.0005558654,0.0004288258,0.0001915418,0.0003113302,0.003208827,0.8203669,0.0007106463,0.002563846,0.1196908],"study_design_scores_gemma":[0.04480139,0.4102902,0.02740324,0.0001107915,0.0008840382,0.001668967,0.0002408952,0.008750401,0.4857585,0.000416071,0.0196164,0.00005899174],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955414,0.002537396,0.0004692365,0.0001119033,0.00002895483,0.0001766986,0.000134455,0.00005688626,0.0009430526],"genre_scores_gemma":[0.9962705,0.001620495,0.0005637456,0.00006864403,0.00002708431,0.0001011834,0.0004462675,0.00001037519,0.000891705],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001120494,"threshold_uncertainty_score":0.003631294,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02619885197197588,"score_gpt":0.3340474590618898,"score_spread":0.3078486070899139,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}